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Introduction
Innate immunity is the immediate ability of a host to
prevent and limit an infectious challenge (Fearon and
Locksley 1996; Medzhitov and Janeway 1997). The bar-
riers to a noxious challenge take on many guises. As new
knowledge accrues, a conceptual congruency in the spec-
trum of innate immunity in a variety of organisms, rang-
ing from plants to humans, is emerging. The recognition
of conserved proteins or domains of proteins has allowed
insights into the evolution of nonclonal first-line host
defenses, so that we are now able to draw analogies
between tobacco plants, fruit flies, frogs, horseshoe
crabs, mice, and humans.
Types of barriers to infection include the skin, the
mucocillary escalator in the lung, antimicrobial peptides,
bacterial-permeability inhibitors, antibodies, the com-
plement system, lipopolysaccharide-binding proteins,
certain classes of lymphocytes, and tissue macrophages.
Although these molecules and cells undoubtedly act in
concert, it is reasonable to assume that a versatile cir-
culating effector molecule would be of added benefit to
the host. Here, I discuss one suchmolecule, themannose-
binding protein (MBP), or mannan-binding lectin, which
appears to play an important role in host defense but
which, under certain circumstances, also may be dele-
terious to the host (Garred et al. 1994; Turner 1996).
MBP as an Ante-antibody: The Dr. Jekyll Role in
Innate Immunity
If one had to design an idealized first-line host-defense
molecule, several features might come to mind. These
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features include the ability to distinguish the self or the
altered self from the nonself, a broad repertoire of rec-
ognition, appropriate regulation and distribution, ade-
quate effector mechanisms, and the ability to trigger a
specific immune response.
Overwhelming in vitro evidence indicates that human
MBP has many of the features of an idealized first-line
host-defense molecule. MBP’s predominant role is as a
so-called ante-antibody (Ezekowitz 1991). Like immu-
noglobulins, MBP binds microorganisms and enhances
their uptake by phagocytic cells. However, as part of the
acute-phase response, MBP is induced rapidly, in a pe-
riod of minutes to hours (Ezekowitz et al. 1988), which
is in contrast with the response period of days required
by the humoral immune system. MBP is synthesized in
the liver but is found in nasopharyngeal secretions, mid-
dle-ear fluid, inflamed joints, and amniotic fluid, as well
as in the serum (Garred et al. 1993; Hoppe et al. 1994;
Molhotra et al. 1994; Epstein et al. 1996; Turner 1996).
Its overall structure resembles the first complement com-
ponent C1q (Drickamer et al. 1986): like C1q, MBP has
globular heads and collagen tails (Lu et al. 1990); and
its monomers assemble as trimers, and its trimers form
oligomers up to hexamers of trimers, which is the C1q-
like configuration. Like C1q, MBP interacts with and
initiates the complement cascade. MBP directly initiates
the classic complement pathway, hence abrogating the
need for an antibody. Two newly discovered, novel
MPB-associated proteases, MASP1 (Matsushita and Fu-
jita 1992; Madsen et al. 1994) and MASP2 (Thiel et al.
1997), directly activate the classic pathway convertase,
and, hence, they mediate the cleavage of complement
component C3 without requiring activation of the C1
complex. Cleaved C3 is an opsonin in which cleavage
represents the common step between the traditionally
defined antibody-dependent and -independent path-
ways. A consensus view is emerging that this MBP, or
so-called lectin, pathway is the primordial mechanism
of complement activation.
MBP recognizes a broad range of infectious agents,
such as gram-positive and gram-negative organisms,
yeast, parasites, mycobacteria, and certain viruses, such
as HIV, the influenza virus, and the herpes virus (Epstein
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Table 1
MBP-Allele Mutations and Frequencies in Three Different
Ethnic Groups
MBP ALLELEa
A B C D
Mutation:
Location Wild-type Exon 1 Exon 1 Exon 1
Codon Wild-type 54 57 52
Amino
acid
change None GlyrAsp GlyrGlu ArgrCys
Frequency:b
Africans
( )n  56 .69 .03 .23 .05
Cauca-
sians (n 
)123 .80 .13 .02 .05
Eskimos
( )n  73 .87 .13 NF NF
Activates
comple-
ment? Yes No ND ND
NOTE.—Adapted from Garred et al. 1992a.
a NF  not found; and ND  not determined.
n  the number of unrelated individuals investigated.
et al. 1996). Thus, MBP is like a broad-spectrum anti-
body that recognizes a range of structural patterns,
rather than a single, defined epitope. The idea of pattern
recognition in host defense was first raised by Janeway
(1989), who postulated that lymphocytes express recep-
tors for the “patterns” or the “antigenic arrays” com-
mon to multiple infectious agents. These lymphocyte re-
ceptors would then be expected to trigger co-stimulatory
activity, an early step in the generation of a clonal im-
mune response. The description of a human homologue
of the Drosophila Toll (see Dushay and Eldon 1998 [in
this issue]) is an important first step in validation of this
concept, although the ligand and hence the pattern rec-
ognized by human TOLL remain to be defined. We have
extended and expanded this concept of pattern recog-
nition to include the circulating effector molecules, as
well as the receptors expressed on the surface of mac-
rophages. Accordingly, we considerMBP to be a pattern-
recognition molecule.
One challenge has been to define the biochemical basis
by which MBP is able to recognize a range of apparently
disparate structures but does not bind self-glycoproteins.
In fact, the pattern recognized by MBP is remarkably
simple. The equatorial orientation of the C3-OH and
C4-OH groups of a sugar moiety defines the pattern
recognized by MBP (Weis et al. 1991; 1992). The pat-
tern, as defined by structural analysis, is represented in
N-acetylglucosamine, glucose, and fucose, as well as in
mannose and the carbohydrate moieties found in the cell
walls of many infectious agents. Importantly, galactose
and sialic acid, the penultimate and ultimate sugars, re-
spectively, that decorate human self-glycoproteins, are
not accommodated within the MBP binding site. In ad-
dition, the crystal structures of the human and the rat
MBP carbohydrate-recognition domains (CRDs) and
neck regions illustrate that the MBP neck region forms
a triple a-helical coil that orients each CRD of human
MBP 45 A˚ or 53 A˚ apart (Sheriff et al. 1994; Weis and
Drickamer 1994). The organization of self-oligosac-
charides appears to be unable to span this distance, un-
like that of the complex-carbohydrate arrays that dec-
orate the surfaces of microorganisms (R. Putzer, R. A.
B. Ezekowitz, and T. Stehle, unpublished data).
MBP in Human Immunity
The importance of MBP in first-line host defense is
supported further by the description of patients who lack
MBP and who have an apparent phenotype of recurrent
infections (Super et al. 1989). Turner et al. (1993) found
an association between a phenotype of recurrent infec-
tions and a polymorphism at codon 54 (B allele; table
1) of the MBP gene that results in the replacement of a
glycine by an aspartic acid, within the collagen region
of MBP (Sumiya et al. 1991). Turner (1996) postulated
that MBP may be particularly important in children !18
mo of age, since competent antibody responses to car-
bohydrate antigens are developed only after this age
(Garred et al. 1992a, 1992b, 1996; Lipscombe et al.
1992; Turner et al. 1993; Madsen et al. 1994, 1995;
Turner 1996). Subsequent studies have revealed two ad-
ditional alleles, the C allele and the D allele. The B allele
results in a G54D substitution at the sixth collagen re-
peat, resulting in an unstable protein and, hence, in very
low to undetectable serum levels of MBP. MBP contain-
ing only the B-type chains can be expressed in vitro, but
it does not bind MASP1 and is unable to activate the
complement. AB heterozygotes have a 20-fold reduction
in MBP levels. The B chain appears to act as a dominant
negative and disrupts the assembly of the collagen helix.
The C allele results in a G57E substitution. AC heter-
ozygotes have intermediate levels of MBP. The D allele
results in a C52D substitution and appears to cause a
milder defect. The frequency of the C allele is ∼33% in
African populations (Garred et al. 1992a, 1992b, 1996;
Lipscombe et al. 1992; Turner et al. 1993; Madsen et
al. 1994, 1995; Turner 1996), whereas the frequency of
the B allele is 13% among Caucasians (table 1).
MBP as Mr. Hyde?
The high frequency of MBP mutations led Garred et
al. (1994) to suggest that, under certain circumstances,
MBP may be protective, whereas under other circum-
stances there may be a selective advantage for the het-
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erozygous state that results in lowMBP levels. According
to this hypothesis, because wild-type MBP can opsonize
parasites or mycobacteria, it actually may assist in the
hematogenous spread of these infectious agents, or it
may enhance the survival of intracellular pathogens. If
this idea is carried a step further, the B and C alleles
would be expected to confer some protection against the
spread of the disease, hence causing the selective advan-
tage of the heterozygote state.
MBP also may function in autoimmune disorders: It
has been found in the fluid isolated from patients with
rheumatoid arthritis, and it appears to be able to bind
agalactosyl antibodies, which bear exposedN-acetylglu-
cosamine moieties—patterns that are recognized by
MBP (Holmskov et al. 1993). When these altered an-
tibodies accumulate, MBP would be expected to bind to
them and activate the complement, thereby stimulating
the inflammatory process. In this regard as well, MBP
alleles that result in low expression levels or those that
fail to activate the complement may be seen as
protective.
In host defense, MBP appears to have a role as an
ante-antibody, serving as a primitive pattern-recognition
molecule that confers protection to the host during the
lag time required for the generation of a specific clonal
immune response. However, under certain circum-
stances, MBP may lead to autoimmune disease or may
facilitate infection by intracellular pathogens. The avail-
ability of suitable mouse models will cast more light on
the insights already gained from the human experience.
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